1. Introduction {#sec1-1}
===============

According to a report published over 10 years ago, elderly patients with schizophrenia accounted for over half of hospitalized elderly patients with mental illness.^\[[@ref11]\]^ In recent years, with the aging of China's population, the number of elderly patients with firstepisode schizophrenia is also gradually increasing. Because therapeutic drugs have pronounced effects on the physiology and biochemistry of elderly persons, it is important to select pharmacological interventions based on sufficient evidence. There is sparse research available on medication selection in this population, therefore we hope that this study will add to the growing body of evidence.

Schizophrenia is a serious mental illness effecting mostly young and middle aged people. For schizophrenia, atypical antipsychotics have been widely used, with reliable curative effects. However, some atypical antipsychotics were found to lead to weight gain in patients.^\[[@ref2],[@ref3]\]^ Generally speaking, taking atypical antipsychotics was a subjectively bad experience for patients as well, especially those who were already overweight. In addition, atypical antipsychotics also tended to increase blood sugar and blood lipids, heightening the risk of cardiovascular and cerebrovascular issues. This combination of side effects often resulted in low medication compliance, which in turn seriously impacted treatment effect. In order to study the efficacy and effects on blood pressure and blood lipid in elderly patients, we chose ziprasidone in the treatment of elderly patients with first-episode schizophrenia and carried out clinical observation.

2. Methods {#sec1-2}
==========

2.1 General information {#sec2-1}
-----------------------

A total of 71 elderly patients were treated at our hospital from March 2012 to April 2016. Among them, 38 patients (21 men and 17 women) met the inclusion criteria and were included in this study. Their age ranged from 60 to 78 years with a mean age of 68.5 years. All patients were randomly divided into the ziprasidone treatment group (i.e. the study group) and the olanzapine treatment group (i.e. the control group), with 19 cases in each group. The study group consisted of 10 men and 9 women, with a mean age of 68.9 years. The control group consisted of 11 mean and 8 women, with a mean age of 68.2 years. There was no significant statistical difference between the two groups.

This study was approved by the Ethics Committee of Huzhou Third People's Hospital of Zhejiang Province.

### Inclusion criteria and exclusion criteria {#sec3-1}

Inclusion criteria were the following: 1) age ≥60 years old, 2) met the diagnostic criteria for schizophrenia according to the *ICD-10 classification of mental and behavioral disorders*,^\[[@ref4]\]^ with a PANSS total score≥60 points, 3) no issues taking ziprasidone or olanzapine, and 4) informed consent was provided by patients' legal guardians.

Exclusion criteria were the following: 1) having diabetes mellitus, hyperlipidemia, or severe liver and renal insufficiency, 2) presence of organic neurological disease such as epilepsy, intracranial infection, brain tumor as determined by MRI or EEG examination, 3) presence of systemic diseases such as systemic lupus erythematosus (SLE), and schizophrenia-like behavior caused by drug intoxication.

Patients were withdrawn from the study if any of the conditions were met: 1) serious complications occurred during the treatment, 2) serious adverse drug reaction, 3) informed consent was withdrawn by the patient's legal guardian, or 4) our researchers collectively determined, based on the patient's condition, that the patient should be withdrawn from the study.

2.2 Methods {#sec2-2}
-----------

In this study, randomized grouping was used with admission time as the compatibility factor, and every fourth patient (as determined by time of admission) were set as an interval for randomized grouping. As a result, 38 cases of elderly patients with firstepisode schizophrenia were randomly divided into the ziprasidone treatment group (study group) and olanzapine treatment group (control group), with 19 cases in each group. Single blind (patient blind) parallel controlled trial design was used.

2.3 Treatment method {#sec2-3}
--------------------

The study group orally took Ziprasidone Hydrochloride Capsules (20 mg per capsule, Jiangsu Nhwa Pharmaceutical Co. Ltd.), with an initial dose of 40 mg/ day (dose ranging from 40 to 120 mg/day, and a mean (sd) dose of 92.4 (4.5) mg/day). The control group orally took olanzapine tablets (5 mg/tablet, Jiangsu Hansoh Pharmaceutical Group. Co. Ltd.,), with an initial dose of 5mg/day (dose ranging 5 to 20 mg/day and a mean (sd) of 9.5 (4.3) mg/day). The two groups both completed a treatment period of 12 weeks without a single case dropping. During treatment, there was no combined use with other antipsychotics, antidepressants, mood stabilizers, or anticonvulsant drugs. In case of adverse reactions, benzodiazepines, trihexyphenidyl hydrochloride, or propranolol was appropriately used for treatment. Ordinary diet was given during the treatment process. Dosage was adjusted according to clinical efficacy and tolerance.

2.4 Observation index and curative effect standard {#sec2-4}
--------------------------------------------------

PANSS, with good reliability and validity,^\[[@ref6]\]^ was used for the evaluation of psychiatric symptoms at the time of admission (baseline), and at the end of 4th, 8th, and 12th weeks of treatment, respectively. The curative effect, based on PANSS score reduction rate, was assigned as follows: ≥75% was considered cured, 50%-74% was considered significant progress, 25% - 49% was considered progress, and \< 25% was considered ineffective. TESS was used for the assessment of adverse reactions.^\[[@ref7]\]^ For each patient, fasting venous blood (4 ml) was collected in the morning for the measurement of FBS, TC, TG, and LDL-c. Liver and kidney functions, electrocardiogram, routine blood test, and routine urine test were inspected once every 2 weeks.

2.5 Statistical methods {#sec2-5}
-----------------------

SPSS 17.0 was used for the statistical analysis. Continuous variables between independent samples were compared using t-test. Repeated measure ANOVA was used to compare the differences between each variable of the two groups during treatment. Rank sum test was used to compare the difference in curative efficacy between the two groups. Statistical significance was set at *p* \< 0.05.

3. Results {#sec1-3}
==========

3.1 Curative effect analysis {#sec2-6}
----------------------------

According to our criteria for PANSS score reduction, in the study group there were: 4 cured cases, 6 cases with significant progress, 5 cases with progress, and 4 ineffective cases. Our standard for effective treatment included the 'cured', 'with significant progress', and 'with progress' designations. Hence, the effectiveness rate was 79.0%, with a cure rate of 21.0%. In the control group there were 3 cured cases, 8 cases with significant progress, 3 cases with progress, and 5 ineffective cases, with an effective rate of 73.7%, and a cure rate of 15.8%. The difference in curative effects of the two groups had no statistical significance. (Mann-Whitney test: *Z* =0.122, **p**=0.903).

3.2 PANSS scores {#sec2-7}
----------------

As shown in [Table 1](#table001){ref-type="table"}, PANSS scores of the two groups were significantly lower after treatment, with statistically significant differences. The total scores of PANSS decreased further with longer treatment duration. However, there was no statistically significant difference between the two groups in the change of total score of PANSS during the treatment **(F**~time×group~=0.009, **p**=0.958).

3.3 Comparison of blood glucose levels {#sec2-8}
--------------------------------------

As shown in [Table 2](#table002){ref-type="table"}, comparing the blood glucose levels between the two groups at each treatment stage, ziprasidone had no significant effect on fasting blood glucose, while fasting blood glucose values increased after treatment in the olanzapine group. The difference between the two groups in change of blood glucose levels during treatment was statistically significant *(F~time×group~=7.539*, **p**=0.001). At the end of 4th, 8th, and 12th weeks respectively, there were statistically significant differences in fasting blood glucose between the ziprasidone group and the olanzapine group.

3.4 Comparison of serum lipid levels {#sec2-9}
------------------------------------

As shown in [Table 3](#table003){ref-type="table"}, comparing the serum lipid levels between the two groups at each treatment stage, the TC, TG and LDL-c levels of the ziprasidone group measured before treatment and at each treatment time point had no statistically significant difference. The TC, TG and LDL-c levels of the olanzapine group measured before treatment and at each treatment time point had statistically significant difference. The difference in the change of each of the serum lipid index levels between the two groups during treatment was also statistically significant (TC: *F~time×group~=*32.194, *p*\<0.001; TG: *F*~time×group~=488.312, p\<0.001; LDL-C: *F~time×group~*=9.380, *p*\<0.001). At the end of 4^th^, 8^th^, and 12^th^ week respectively, there were statistically significant differences in TC, TG and LDL-c levels between the ziprasidone group and the olanzapine group.

3.5 Side effects {#sec2-10}
----------------

Till the end of the study, side effects in the ziprasidone group included 1 case of skin rash, 2 cases of nausea, 1 case of constipation, 1 case of muscle rigidity, and 1 case of dry mouth. Side effects in the olanzapine group included 2 cases of sleepiness, 5 cases of significant body weight gain, 1 case of constipation, and 1 case of dry mouth. The control group had significantly more cases of sleepiness and significant body weight gain than the study group (accurate estimation *p*=0.045). There was no significant difference between the two groups in the overall side effect ratios. The changes in liver and renal functions, electrocardiogram, and routine blood and urine test results of the two groups of patients were within the normal range, without statistically significant differences compared with pre-treatment conditions.

4. Discussion {#sec1-4}
=============

4.1 Main findings {#sec2-11}
-----------------

It was found in this study that ziprasidone and olanzapine had comparable curative effects in the treatment of schizophrenia in elderly patients. The ziprasidone group had an effectiveness rate of 79.0%, with a cure rate of 21.0%. The olanzapine group had an effectiveness rate of 73.7%, with a cure rate of 15.8%. Between the two groups, the PANSS scores in each treatment stage had no significant difference, indicating that ziprasidone and olanzapine had comparable curative effects in the treatment of elderly patients with first-episode schizophrenia. Meanwhile, there was no difference in onset time, which is consistent with the literature.^\[[@ref8],[@ref9]\]^

Comparing the blood glucose and lipid levels in each treatment stage between the two groups, there were significant differences. Ziprasidone had less effect on patients' blood glucose and serum lipid, which was consistent with the results from a study by Cui and colleagues.^\[[@ref10]\]^ Olanzapine had the function of raising blood glucose and serum lipid levels. This was consistent with results from Koike and colleagues,^\[[@ref11]\]^ which reported diabetes caused by olanzapine.

For the two groups, extrapyramidal side effects (such as muscle stiffness) had a relatively low incidence rate, which could be related to the higher 5-serotonin (5-HT) receptor affinity than the D2 receptor.^\[[@ref12]\]^ In this study, the intervention group and the control group had comparable ratios of curative effects and overall side effects. But the control group had fairly significant sleepiness and weight gain. Sleepiness and weight gain had reciprocal interactions, for which the root cause could be closely related to sugar and lipid metabolism.

4.2 Limitations {#sec2-12}
---------------

Metabolic syndrome, i.e. abnormal glucose metabolism (hyperglycemia), abnormal lipids metabolism (dyslipidemia), elevated blood pressure, and abdominal obesity are serious side effects from atypical antipsychotics that require attention. The advantage of ziprasidone differentiating it from other atypical antipsychotics is that it has almost no risk of causing metabolic syndrome. However, the mechanism of its effects on the metabolisms of carbohydrates and lipids is still not clear, requiring further study. In this study, the sample size was small, and a single blind randomized design was used, which could impact the results. Future studies should use a double-blind randomized study design with a larger sample size.

4.3 Implications {#sec2-13}
----------------

At present, the etiology of schizophrenia is not clear. The treatment of schizophrenia mainly involves the longterm use of drugs affecting the neurotransmitters of the central nervous system. Different drugs have different mechanisms, side effects and metabolic pathways, effecting the body in a variety of ways.

Elderly peoples' various organ functions, such as in the digestive system, liver, pancreas, urinary system, nervous system and endocrine system, are significantly reduced. Therefore, impact on organ functioning must be considered when prescribing medications for schizophrenia in elderly patients. A personalized treatment plan, after carefully considering the effects of each medication, is ideal. For patients with schizophrenia, a well applied use of antipsychotic medication can play a crucial role in treatment. As schizophrenia usually persists and develops progressively, elderly patients with decreased metabolism and immunity require a longer time for treatment. In addition, it is common to see other chronic diseases in elderly patients such as cardiovascular and cerebrovascular diseases. Control of blood glucose and lipid levels in the treatment of schizophrenia may reduce the risk of cardiovascular and cerebrovascular accidents. Therefore it is of great clinical significance to select antipsychotic medications for elderly patients which have little effect on blood glucose and blood lipids.

Ziprasidone in the treatment of schizophrenia in elderly patients was reliably effective and had little effect on their glucose and lipid metabolism. Ziprasidone can reduce the risk of cardiovascular and cerebrovascular incidents, improve medication compliance in elderly patients and ensure long-term effectiveness of pharmacological treatment.

For patients with cardiovascular risks, especially elderly patients with schizophrenia who have comorbid metabolism related diseases, obesity, or family history of cardiovascular disease, ziprasidone is a potentially suitable medication choice.
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###### 

Statistical comparison of PANSS total scores (mean\[SD\]) of the two groups in each treatment stage

  Group           Before treatment   4^th^ week   8^th^ week   12^th^ week   *F~time~*     *P~time~*   *F~group~*   *P~group~*   *F~time×group~*   *P~time×group~*   
  --------------- ------------------ ------------ ------------ ------------- ------------- ----------- ------------ ------------ ----------------- ----------------- -------
  Study group                        84.8 (8.0)   67.0 (4.5)   54.1 (8.8)    42.1 (14.8)   54.83       \<0.001      0.38         0.543             0.01              0.958
  Control group                      85.4 (6.2)   68.7 (6.7)   55.4 (9.9)    43.0 (16.4)                                                                             
  Between-group   *F*                0.07         0.83         0.19          0.04                                                                                    
  *P*             0.787              0.370        0.667        0.853                                                                                                 

Note: \*For the study group, repeated measures of variance was used to analyze the comparison results of PANSS scores of the two groups before treatment and after 4^th^, 8^th^, and 12^th^ weeks of treatment. F values were 78.811, 79.780, and 72.822, respectively. *P* values were \<0.001.

For the control group, repeated measures of variance was used to analyze the comparison results of PANSS scores of the two groups before treatment and after 4^th^, 8^th^, and 12^th^ weeks of treatment. F values were 41.335, 77.337, and 75.435, respectively. *P* values were \<0.001.

###### 

Statistical comparison of blood glucose level (mean\[SD\]) mmol/L of the two groups in each treatment stage

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Group           Before treatment   4^th^ week   8^th^ week    12^th^ week   *F~time~*     *P~time~*   *F~group~*   *P~group~*   *F~time×group~*   *P~time×group~*   
  --------------- ------------------ ------------ ------------- ------------- ------------- ----------- ------------ ------------ ----------------- ----------------- -------
  Study group                        5.28(0.66)   5.54 (1.10)   5.56\         5.59 (1.02)   12.45       \<0.001      5.70         0.022             7.54              0.001
                                                                (1.09)                                                                                                

  Control group                      5.41(0.65)   6.42 (1.12)   6.56\         7.28 (2.22)                                                                             
                                                                (1.55)                                                                                                

  Between-group   *F*                0.01         5.93          5.34          9.12                                                                                    

  *P*             0.912              0.020        0.027         0.005                                                                                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**N**ote: \*The results of study group after 4^th^, 8^th^, and 12^th^ weeks of treatment compared with the results before treatment. F values were 1.448, 1.765, and 3.193, respectively. *P* values were 0.238, 0.201, and 0.091.

The results of control group after 4^th^, 8^th^, and 12^th^ weeks of treatment compared with the results before treatment. F values were 42.943, 21.080, and 22.339, respectively. *P* values were \<0.001.

###### 

Comparison of blood lipids level (mean\[SD\]) mmol/L of the two groups in each treatment stage

  Group                 blood lipid indices   Before treatment                                4^th^ week                                      8^th^ week                                      12^th^ week
  --------------------- --------------------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- -----------------------------------------------
  Study group(n=19)     TC                    4.08(0.67)                                      4.10(0.58) [\*](#tfn001){ref-type="table-fn"}   4.14(0.60) [\*](#tfn001){ref-type="table-fn"}   4.13(0.67) [\*](#tfn001){ref-type="table-fn"}
  TG                    1.25(0.21)            1.21(0.25) [\*](#tfn001){ref-type="table-fn"}   1.27(0.26) [\*](#tfn001){ref-type="table-fn"}   1.28(0.20) [\*](#tfn001){ref-type="table-fn"}   
  LDL-c                 2.57(0.23)            2.60(0.23) [\*](#tfn001){ref-type="table-fn"}   2.61(0.25) [\*](#tfn001){ref-type="table-fn"}   2.60(0.29) [\*](#tfn001){ref-type="table-fn"}   
  Control group(n=19)   TC                    4.14(0.66)                                      4.61(0.64)△                                     4.69(0.84)△                                     4.83(0.83)△
  TG                    1.21(0.24)            1.97(0.33)△                                     2.04(0.45)△                                     2.24(0.31)△                                     
  LDL-c                 2.60(0.21)            2.81(0.33)△                                     2.95(0.44)△                                     3.08(0.53)△                                     

\*study group after 4^th^, 8^th^, and 12^th^ weeks of treatment compared with the results before treatment:

For TC, the F values were 0.372, 3.651, and 2.069, respectively. The *P* values were 0.550, 0.072, and 0.167, respectively.

For TG, the F values were 1.436, 0.960, and 1.584, respectively. The *P* values were 0.246, 0.340, and 0.224, respectively.

For LDL-c, the F values were 3.589, 4.264, and 2.736, respectively. The P values were 0.074, 0.054, and 0.115, respectively.

△control group after 4^th^, 8^th^, and 12^th^ weeks of treatment compared with the results before treatment:

For TC, the F values were 88.724, 61.057, and 86.144, respectively. *P* values were \<0.001.

For TG, the F values were 554.839, 256.301, and 1865.620, respectively. *P* values were \<0.001.

For LDL-c, the F values were 42.611, 34.394, and 38.412, respectively. *P* values were \<0.001.
